Drug intelligence / Profile preview

ABS-280

Development stage: Preclinical
Lead developer: Amberstone Biosciences
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

ABS-280 is a fusion protein drug candidate classified as an immunomodulator. It was initially developed by Amberstone Biosciences and is being investigated for the treatment of neoplasms, specifically solid tumors. The mechanism of action involves modulation of the immune system, but further molecular details have not been disclosed publicly. As of May 2025, its highest development status is at the discovery stage and it has not entered clinical trials or received regulatory approval[1][2].

Beyond the preview

Go deeper on ABS-280.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABS-280.

Explore the full profile